PureTech Health (LON:PRTC) Hits New 12-Month Low – Should You Sell?

PureTech Health plc (LON:PRTC) reached a new 52-week low during trading on Thursday . The stock traded as low as GBX 123.20 ($1.59) and last traded at GBX 135.40 ($1.74), with a volume of 26766676 shares trading hands. The stock had previously closed at GBX 127.20 ($1.64).

Analyst Ratings Changes

Separately, Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 455 ($5.86) target price on shares of PureTech Health in a research note on Monday, December 16th.

PureTech Health Price Performance

The company has a 50 day moving average of GBX 139.83 and a 200 day moving average of GBX 149.92. The company has a debt-to-equity ratio of 45.82, a quick ratio of 2.51 and a current ratio of 3.68. The stock has a market capitalization of £406.72 million, a price-to-earnings ratio of -5.55 and a beta of 1.02.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.